Berenberg Bank Believes Xencor (XNCR) Still Has Room to Grow


Berenberg Bank analyst Zhiqiang Shu assigned a Buy rating to Xencor (XNCR) on November 6. The company’s shares closed last Monday at $40.58, close to its 52-week high of $43.90.

According to TipRanks.com, Shu is a 3-star analyst with an average return of 19.5% and a 90.0% success rate. Shu covers the Healthcare sector, focusing on stocks such as Seattle Genetics, Morphosys Ag, and BioNTech SE.

Xencor has an analyst consensus of Moderate Buy, with a price target consensus of $47.50, a 13.5% upside from current levels. In a report issued on November 5, Mizuho Securities also maintained a Buy rating on the stock with a $52.00 price target.

See today’s analyst top recommended stocks >>

Based on Xencor’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $35.37 million and GAAP net loss of $12.55 million. In comparison, last year the company earned revenue of $21.76 million and had a GAAP net loss of $10.22 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts